Cited by 2,641Clostridium difficile and Clostridium perfringens researchInfection Control in HealthcareAntimicrobial Resistance in Staphylococcus

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Burden of Clostridium difficile Infection in the United States

Open access

Lessa, Fernanda C., Mu, Yi, Bamberg, Wendy M., Beldavs, Zintars G., Dumyati, Ghinwa K., Dunn, John R., Farley, Monica M., Holzbauer, Stacy M., Meek, James I., Phipps, Erin C., Wilson, Lucy E., Winston, Lisa G., Cohen, Jessica A., Limbago, Brandi M., Fridkin, Scott K., Gerding, Dale N., McDonald, L. Clifford·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1408913PMC PMC10966662

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The magnitude and scope of Clostridium difficile infection in the United States continue to evolve. METHODS: In 2011, we performed active population- and laboratory-based surveillance across 10 geographic areas in the United States to identify cases of C. difficile infection (stool specimens positive for C. difficile on either toxin or molecular assay in residents ≥ 1 year of age). Cases were classified as community-associated or health care-associated. In a sample of cases of C. difficile infection, specimens were cultured and isolates underwent molecular typing. We used regression models to calculate estimates of national incidence and total number of infections, first recurrences, and deaths within 30 days after the diagnosis of C. difficile infection. RESULTS: A total of 15,461 cases of C. difficile infection were identified in the 10 geographic areas; 65.8% were health care-associated, but only 24.2% had onset during hospitalization. After adjustment for predictors of disease incidence, the estimated number of incident C. difficile infections in the United States was 453,000 (95% confidence interval [CI], 397,100 to 508,500). The incidence was estimated to be higher among females (rate ratio, 1.26; 95% CI, 1.25 to 1.27), whites (rate ratio, 1.72; 95% CI, 1.56 to 2.0), and persons 65 years of age or older (rate ratio, 8.65; 95% CI, 8.16 to 9.31). The estimated number of first recurrences of C. difficile infection was 83,000 (95% CI, 57,000 to 108,900), and the estimated number of deaths was 29,300 (95% CI, 16,500 to 42,100). The North American pulsed-field gel electrophoresis type 1 (NAP1) strain was more prevalent among health care-associated infections than among community-associated infections (30.7% vs. 18.8%, P<0.001). CONCLUSIONS: C. difficile was responsible for almost half a million infections and was associated with approximately 29,000 deaths in 2011. (Funded by the Centers for Disease Control and Prevention.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1408913

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Self-citation
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pépin, J., & Wilcox, M. H. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,931
Self-citation
Sampling: Design and Analysis
Ziegel, E. R., & Lohr, S. L. (2000) · Technometrics · doi:10.2307/1271491 · Cited by 2,452
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G., Thompson, A. D., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,020
Self-citation
A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M., Michaud, S., Bourgault, A., Nguyen, T., Frenette, C. H., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,962
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., BENTHEM, B. H. B. V., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,049
The Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, A., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 838
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R. P., Gerding, D. N., Nichol, G. M., Thomas, W. D., Leney, M. D., Sloan, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 743
Self-citation
Burden of Clostridium difficile on the Healthcare System
Dubberke, E. R., & Olsen, M. A. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis335 · Cited by 566
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection
Planche, T., Davies, K., Coen, P. G., Finney, J. M., Monahan, I. M., Morris, K. A., O’Connor, L., Oakley, S. J., Pope, C. F., Wren, M. W. D., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70200-7 · Cited by 436

Flagged first, then by citations

Show all 44 references

Research works printed but not linked: 4

2005, MMWR Morb Mortal Wkly Rep, 54, 1201
Heitjan DF, 1991, J R Stat Soc Ser C Appl Stat, 40, 13
2014, Fed Regist, 79, 10524
2011, Fed Regist, 76, 51476

Sorted by citations

Items 501–600 of 1,002

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
Hise, N. V., Petrak, R. M., Skorodin, N. C., Fliegelman, R. M., Anderson, M., Didwania, V., Han, A., Shah, K. J., Chundi, V. V., Hines, D. W., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00351-0 · Cited by 43
Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives
Cymbal, M., Chatterjee, A. B., Baggott, B. B., & Aurón, M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.03.024 · Cited by 42
Clostridioides difficile Toxins: Host Cell Interactions and Their Role in Disease Pathogenesis
Alam, M. Z., & Madan, R. (2024) · Toxins · doi:10.3390/toxins16060241 · Cited by 42
Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis
Lübbert, C., Zimmermann, L., Borchert, J., Hörner, B., Mutters, R., & Rodloff, A. C. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0135-9 · Cited by 42
The emerging metabolic view of Clostridium difficile pathogenesis
Hryckowian, A. J., Pruss, K. M., & Sonnenburg, J. L. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.11.006 · Cited by 44
Clostridium difficile colitis: A clinical review
Ong, G. K. B., Reidy, T. J., Huk, M. D., & Lane, F. R. (2017) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.10.035 · Cited by 42
Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI)
Jiang, Z., Alexander, A., Shi, K., Valilis, E., Hu, S., Li, B., & DuPont, H. L. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.08.003 · Cited by 42
Prediction of RecurrentClostridium DifficileInfection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System
Escobar, G. J., Baker, J. M., Kipnis, P., Greene, J., Mast, T. C., Gupta, S. B., Cossrow, N., Mehta, V., Liu, V. X., & Dubberke, E. R. (2017) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.176 · Cited by 42
Toxigenic Clostridium difficile carriage in general practice: results of a laboratory-based cohort study
Barbut, F., Day, N., Bouée, S., Youssouf, A., Grandvoinnet, L., Lalande, V., Couturier, J., & Eckert, C. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.024 · Cited by 42
Natural Clostridioides difficile Toxin Immunization in Colonized Infants
Kociolek, L. K., Espinosa, R. O., Gerding, D. N., Hauser, A. R., Ozer, E. A., Budz, M., Balaji, A., Chen, X., Tanz, R. R., Yalçınkaya, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz582 · Cited by 42
Self-citation
Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship
Crotty, M. P., Meyers, S., Hampton, N. B., Bledsoe, S., Ritchie, D. J., Buller, R. S., Storch, G. A., Kollef, M. H., & Micek, S. T. (2015) · Critical Care · doi:10.1186/s13054-015-1120-5 · Cited by 43
Functional analyses of epidemic Clostridioides difficile toxin B variants reveal their divergence in utilizing receptors and inducing pathology
Pan, Z., Zhang, Y., Luo, J., Li, D., Zhou, Y., He, L., Yang, Q., Dong, M., & Tao, L. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009197 · Cited by 41
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection
Poylin, V. Y., Hawkins, A. T., Bhama, A. R., Boutros, M., Lightner, A. L., Khanna, S., Paquette, I. M., & Feingold, D. L. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002047 · Cited by 43
Effect of a Clostridium difficile Infection Prevention Initiative in Veterans Affairs Acute Care Facilities
Evans, M. E., Kralovic, S. M., Simbartl, L. A., Jain, R., & Roselle, G. A. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.27 · Cited by 41
A Clostridium difficile -Specific, Gel-Forming Protein Required for Optimal Spore Germination
Donnelly, M. L., Li, W., Li, Y.-Q., Hinkel, L. A., Setlow, P., & Shen, A. (2017) · mBio · doi:10.1128/mbio.02085-16 · Cited by 41
Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco‐2 cells
Gigli, S., Seguella, L., Pesce, M., Bruzzese, E., D’Alessandro, A., Cuomo, R., Steardo, L., Sarnelli, G., & Esposito, G. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617698622 · Cited by 42
Silver potentiates aminoglycoside toxicity by enhancing their uptake
Hérisse, M., Duverger, Y., Martin‐Verstraete, I., Barras, F., & Ezraty, B. (2017) · Molecular Microbiology · doi:10.1111/mmi.13687 · Cited by 41
Peptidoglycan Cross-Linking Activity of l , d -Transpeptidases from Clostridium difficile and Inactivation of These Enzymes by β-Lactams
Sütterlin, L., Edoo, Z., Hugonnet, J., Mainardi, J., & Arthur, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01607-17 · Cited by 41
Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review
Iqbal, U., Anwar, H., & Karim, M. A. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001147 · Cited by 41
Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature
Lin, S. C., Alonso, C. D., & Moss, A. C. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12967 · Cited by 41
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Alonso, C. D., & Mahoney, M. V. G. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s159957 · Cited by 41
The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity
Leslie, J. L., Vendrov, K. C., Jenior, M. L., & Young, V. B. (2019) · mSphere · doi:10.1128/mspheredirect.00698-18 · Cited by 41
Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population
Morrisette, T., Matre, A. V., Miller, M. A., Mueller, S. W., Bajrovic, V., Abidi, M. Z., Benamu, E., Kaiser, J. N., Barber, G. R., Chase, S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.021 · Cited by 41
Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci
Stevens, V. W., Khader, K., Echevarria, K. L., Nelson, R. E., Zhang, Y., Jones, M., Timbrook, T. T., Samore, M. H., & Rubin, M. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz871 · Cited by 40
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
Lomeli, B., Galbraith, H., Schettler, J., Saviolakis, G. A., Elamin, W. F., Osborn, B. L., Ravel, J., Hazleton, K. Z., Lozupone, C., Evans, R. J., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01395-19 · Cited by 41
An update on our understanding of Gram-positive bacterial membrane vesicles: discovery, functions, and applications
Xu, Y., Xie, C., Liu, Y., Qin, X., & Liu, J. J. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1273813 · Cited by 40
Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection
Khanna, S., Gupta, A., Baddour, L. M., & Pardi, D. S. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1366-6 · Cited by 40
Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model ofClostridium difficileInfection
van Opstal, E. J., Kolling, G. L., Moore, J. H., Coquery, C. M., Wade, N. S., Loo, W. M., Bolick, D. T., Shin, J. H., Erickson, L. D., & Warren, C. A. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw071 · Cited by 39
Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection
Khanna, S., & Pardi, D. S. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1158097 · Cited by 41
Targeting the ecology within: The role of the gut–brain axis and human microbiota in drug addiction
Skosnik, P. D., & Cortes-Briones, J. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.05.021 · Cited by 40
Body mass index greater than 35 is associated with severe Clostridium difficile infection
Mulki, R., Baumann, A. J., Alnabelsi, T. S., Sandhu, N., Alhamshari, Y., Wheeler, D., Perloff, S. R., & Katz, P. O. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13832 · Cited by 40
Incidence, Risk Factors, and Impact of Clostridium difficile Colitis Following Primary Total Hip and Knee Arthroplasty
Bovonratwet, P., Bohl, D. D., Malpani, R., Nam, D., Valle, C. J. D., & Grauer, J. N. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2017.08.004 · Cited by 40
Risk of Clostridium difficile Infection in Patients With Celiac Disease: A Population-Based Study
Lebwohl, B., Nobel, Y. R., Green, P. H. R., Blaser, M. J., & Ludvigsson, J. F. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.400 · Cited by 40
Economic burden and cost-effective management of Clostridium difficile infections
Heimann, S. M., Aguilar, M. R. C., Mellinghof, S., & Vehreschild, M. J. G. T. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2017.10.010 · Cited by 40
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
Momani, L. A. A., Abughanimeh, O. K. M., Boonpherg, B., Gabriel, J. G., & Young, M. (2018) · Cureus · doi:10.7759/cureus.2778 · Cited by 40
Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016–2017 data from US hospitals
Tabak, Y. P., Srinivasan, A., Yu, K. C., Kurtz, S. G., Gupta, V., Gelone, S. P., Scoble, P. J., & McDonald, L. C. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.236 · Cited by 40
Self-citation
Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases
Deshpande, A., Wu, X., Huo, W., Palmer, K. L., & Hurdle, J. G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00415-20 · Cited by 40
Consumption of a Western-Style Diet Modulates the Response of the Murine Gut Microbiome to Ciprofloxacin
Cabral, D. J., Wurster, J. I., Korry, B. J., Penumutchu, S., & Belenky, P. A. (2020) · mSystems · doi:10.1128/msystems.00317-20 · Cited by 45
Behavioral Economics and Ambulatory Antibiotic Stewardship: A Narrative Review
Richards, A. R., & Linder, J. A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.08.004 · Cited by 46
Current and future applications of fecal microbiota transplantation for children
Chen, C.-C., & Chiu, C. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.11.004 · Cited by 41
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial
Garey, K. W., McPherson, J. K., Dinh, A. Q., Hu, C., Jo, J., Wang, W., Lancaster, C. K., Gonzales-Luna, A. J., Loveall, C., Begum, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac096 · Cited by 40
The microbiota and immune response during Clostridium difficile infection
Buonomo, E. L., & Petri, W. A. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.009 · Cited by 47
Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium
Reed, A. D., & Theriot, C. M. (2021) · Microorganisms · doi:10.3390/microorganisms9020371 · Cited by 39
Antibiotics for the urgent management of symptomatic irreversible pulpitis, symptomatic apical periodontitis, and localized acute apical abscess
Tampi, M. P., Pilcher, L., Urquhart, O., Kennedy, E., O’Brien, K. K., Lockhart, P. B., Abt, E., Aminoshariae, A., Durkin, M. J., Fouad, A. F., et al. (2019) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2019.09.011 · Cited by 39
Discovery and development of surotomycin for the treatment of Clostridium difficile
Knight-Connoni, V., Mascio, C. T. M., Chesnel, L., & Silverman, J. A. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1714-6 · Cited by 39
The Rhoptry Pseudokinase ROP54 Modulates Toxoplasma gondii Virulence and Host GBP2 Loading
Kim, E. W., Nadipuram, S. M., Tetlow, A. L., Barshop, W. D., Liu, P. T., Wohlschlegel, J. A., & Bradley, P. J. (2016) · mSphere · doi:10.1128/msphere.00045-16 · Cited by 41
Probiotics as adjunctive therapy for preventing Clostridium difficile infection – What are we waiting for?
Spinler, J. K., Ross, C. L., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.007 · Cited by 39
The Conserved Spore Coat Protein SpoVM Is Largely Dispensable in Clostridium difficile Spore Formation
Ribis, J. W., Ravichandran, P., Putnam, E. E., Pishdadian, K., & Shen, A. (2017) · mSphere · doi:10.1128/msphere.00315-17 · Cited by 39
Ribotypes and New Virulent Strains Across Europe
Couturier, J., Davies, K., Gateau, C., & Barbut, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_4 · Cited by 39
Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology
Sandlund, J., Bartolome, A., Almazan, A., Tam, S., Biscocho, S., Abusali, S., Bishop, J. J., Nolan, N. P., Estis, J., Todd, J. A., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00908-18 · Cited by 39
A systematic review of the use of rifaximin for Clostridium difficile infections
Ng, Q. X., Loke, W., Foo, N. X., Mo, Y., Yeo, W. S., & Soh, A. Y. S. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.10.011 · Cited by 39
A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides ( Clostridium ) difficile in Adults
Kraft, C. S., Parrott, J. S., Cornish, N. E., Rubinstein, M. L., Weissfeld, A. S., McNult, P., Nachamkin, I., Humphries, R. M., Kirn, T. J., Bard, J. D., et al. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00032-18 · Cited by 40
Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain
Carlson, T. J., Blasingame, D., Gonzales-Luna, A. J., Alnezary, F. S., & Garey, K. W. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102142 · Cited by 38
Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
Qian, X., Yanagi, K., Kane, A. V., Alden, N., Lei, M., Snydman, D. R., Vickers, R. J., Lee, K., & Thorpe, C. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00046.2020 · Cited by 40
Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection
Kunishima, H., Ohge, H., Suzuki, H., Nakamura, A., Matsumoto, K., Mikamo, H., Mori, N., Morinaga, Y., Yanagihara, K., Yamagishi, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.011 · Cited by 39
Pulsed-xenon ultraviolet light disinfection in a burn unit: Impact on environmental bioburden, multidrug-resistant organism acquisition and healthcare associated infections
Green, C., Pamplin, J. C., Chafin, K. N., Murray, C. K., & Yun, H. C. (2016) · Burns · doi:10.1016/j.burns.2016.08.027 · Cited by 39
Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice
Jose, S., Mukherjee, A., Horrigan, O., Setchell, K. D. R., Zhang, W., Moreno‐Fernandez, M. E., Andersen, H. M., Sharma, D., Haslam, D. B., Divanovic, S., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00338-7 · Cited by 40
Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS)
Ticinesi, A., Nouvenne, A., Folesani, G., Prati, B., Morelli, I., Guida, L., Turroni, F., Ventura, M., Lauretani, F., Maggio, M. G., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009316 · Cited by 38
Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis
Dubberke, E. R., Olsen, M. A. A., Stwalley, D. L., Kelly, C. P., Gerding, D. N., Young‐Xu, Y., & Mahé, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146822 · Cited by 38
Self-citation
Antibiotics and the Intestinal Microbiome: Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections
Thiemann, S., Smit, N., & Strowig, T. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_504 · Cited by 44
Toxin profiles, PCR ribotypes and resistance patterns of Clostridium difficile : a multicentre study in China, 2012–2013
Gao, Q., Wu, S., Huang, H., Ni, Y., Chen, Y., Hu, Y., & Yu, Y. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.009 · Cited by 38
Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review
Le, P., Nghiem, V. T. H., Mullen, P. D., & Deshpande, A. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.303 · Cited by 39
Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population
Olsen, M. A. A., Stwalley, D. L., Demont, C., & Dubberke, E. R. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy160 · Cited by 38
Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineage
Eyre, D. W., Didelot, X., Buckley, A. M., Freeman, J., Moura, I. B., Crook, D. W., Peto, T., Walker, A. S., Wilcox, M. H., & Dingle, K. E. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.038 · Cited by 38
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016
Thorpe, C. M., McDermott, L. A., Tran, M. K., Chang, J. H., Jenkins, S. G., Goldstein, E. J. C., Patel, R., Forbes, B. A., Johnson, S., Gerding, D. N., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00391-19 · Cited by 38
Self-citation
Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection
Frisbee, A. L., & Petri, W. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.009 · Cited by 42
Genomic Determination of Relative Risks for Clostridioides difficile Infection From Asymptomatic Carriage in Intensive Care Unit Patients
Worley, J. N., Delaney, M. L., Cummins, C. K., DuBois, A. M., Klompas, M., & Bry, L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa894 · Cited by 38
The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σ V in Response to Lysozyme
Woods, E. C., Nawrocki, K. L., Suárez, J. M., & McBride, S. M. (2016) · Infection and Immunity · doi:10.1128/iai.00207-16 · Cited by 43
Considerations for responsible antibiotic use in dentistry
Fluent, M. T., Jacobsen, P. L., & Hicks, L. A. (2016) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2016.04.017 · Cited by 38
Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile–Associated Diarrhea: A Phase 2a Multicenter Clinical Trial
O’Gorman, M. A., Michaels, M. G., Kaplan, S. L., Otley, A. R., Kociolek, L. K., Hoffenberg, E. J., Kim, K. S., Nachman, S., Pfefferkorn, M. D., Sentongo, T. A. S., et al. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix037 · Cited by 38
Small Prokaryotic DNA-Binding Proteins Protect Genome Integrity throughout the Life Cycle
Molan, K., & Bertok, D. Ž. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074008 · Cited by 37
Clostridium difficile in Older Adults
Donskey, C. J. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.07.003 · Cited by 37
Associations of prenatal exposure to polybrominated diphenyl ethers and polychlorinated biphenyls with long-term gut microbiome structure: a pilot study
Laue, H. E., Brennan, K. J. M., Gillet, V., Abdelouahab, N., Coull, B. A., Weisskopf, M. G., Burris, H. H., Zhang, W., Takser, L., & Baccarelli, A. (2019) · Environmental Epidemiology · doi:10.1097/ee9.0000000000000039 · Cited by 37
Probing Clostridium difficile Infection in Complex Human Gut Cellular Models
Anonye, B. O., Hassall, J., Patient, J. D., Detamornrat, U., Aladdad, A. M., Schüller, S., Rose, F. R. A. J., & Unnikrishnan, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00879 · Cited by 37
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
van Werkhoven, C. H., Ducher, A., Berkell, M., Mysara, M., Lammens, C., Torre‐Cisneros, J., Rodríguez‐Baño, J., Herghea, D., Cornely, O. A., Biehl, L. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22269-y · Cited by 37
The Environment, Farm Animals and Foods as Sources of Clostridioides difficile Infection in Humans
Bolton, D., & Marcos, P. (2023) · Foods · doi:10.3390/foods12051094 · Cited by 38
Acute Kidney Injury Due to Diarrheal Illness Requiring Hospitalization: Data from the National Inpatient Sample
Bradshaw, C., Zheng, Y., Silver, S. A., Chertow, G. M., Long, J., & Anand, S. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4531-6 · Cited by 36
A commensal protozoan attenuates Clostridioides difficile pathogenesis in mice via arginine-ornithine metabolism and host intestinal immune response
Yang, H., Wu, X., Xiao, L., Zang, W., Zhou, Z., Zhou, Y., Cui, W., Kou, Y., Wang, L., Hu, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47075-0 · Cited by 36
Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection
McMillan, A. S., Zhang, G., Dougherty, M., McGill, S., Gulati, A., Baker, E. S., & Theriot, C. M. (2024) · mSphere · doi:10.1128/msphere.00706-24 · Cited by 40
Management of Clostridium difficile Infection.
Al-Jashaami, L., & DuPont, H. L. (2016) · PubMed Central · Cited by 36
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection
Leber, A. J., Hontecillas, R., Abedi, V., Tubau‐Juni, N., Zoccoli-Rodriguez, V., Stewart, C., & Bassaganya-Riera, J. (2017) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.05.003 · Cited by 36
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
Kufel, W. D., Devanathan, A. S., Marx, A. H., Weber, D. J., & Daniels, L. M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1990 · Cited by 37
Critically ill patients and gut motility: Are we addressing it?
Vazquez-Sandoval, A., Ghamande, S. A., & Surani, S. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.174 · Cited by 36
Faecal microbiota transplantation: a regulatory hurdle?
Verbeke, F., Janssens, Y., Wynendaele, E., & Spiegeleer, B. D. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0687-5 · Cited by 36
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis
Mintz, M. J., Khair, S., Grewal, S., LaComb, J. F., Park, J., Channer, B., Rajapakse, R. O., Bucobo, J. C., Buscaglia, J. M., Monzur, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190997 · Cited by 35
The role of zinc and nutritional immunity inClostridium difficileinfection
Zackular, J. P., & Skaar, E. P. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1448354 · Cited by 36
Healthcare-associated Clostridium difficile infection: role of correct hand hygiene in cross-infection control
Ragusa, R., Giorgianni, G., Lupo, L., Sciacca, A., Rametta, S., Verde, M., Mule, S., & Marranzano, M. (2018) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2018.59.2.923 · Cited by 36
Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship study
Christensen, A. B., Barr, V. O., Martin, D. W., Anderson, M., Gibson, A. K., Hoff, B. M., Sutton, S. H., Widmaier, V., Salim, A. A., Silkaitis, C., et al. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.336 · Cited by 36
Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases
Fujimoto, K., Kawaguchi, Y., Shimohigoshi, M., Gotoh, Y., Nakano, Y., Usui, Y., Hayashi, T., Kimura, Y., Uematsu, M., Yamamoto, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.021 · Cited by 40
Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence
Lei, D. K., Ollech, J. E., Andersen, M. J., Weisshof, R., Zmeter, N., Sossenheimer, P. H., & Rubin, D. T. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000460 · Cited by 36
Hospital Infection Control: Clostridioides difficile
Turner, N., & Anderson, D. J. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701234 · Cited by 36
Regulatory effects of transition metals supplementation/deficiency on the gut microbiota
Li, C., Li, X., Shen, L., & Ji, H. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11096-2 · Cited by 35
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
Gonzales-Luna, A. J., Olaitan, A. O., Shen, W., Deshpande, A., Carlson, T. J., Dotson, K. M., Lancaster, C. K., Begum, K., Alam, M. J., Hurdle, J. G., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab365 · Cited by 36
Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
Yu, H., Alfred, T., Nguyen, J. L., Zhou, J., & Olsen, M. A. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac467 · Cited by 36
ZupT Facilitates Clostridioides difficile Resistance to Host-Mediated Nutritional Immunity
Zackular, J. P., Knippel, R. J., Lopez, C. A., Beavers, W. N., Maxwell, C. N., Chazin, W. J., & Skaar, E. P. (2020) · mSphere · doi:10.1128/msphere.00061-20 · Cited by 35
Elucidating human gut microbiota interactions that robustly inhibit diverse Clostridioides difficile strains across different nutrient landscapes
Sulaiman, J. E., Thompson, J. C., Qian, Y., Vivas, E. I., Diener, C., Gibbons, S. M., Safdar, N., & Venturelli, O. S. (2024) · Nature Communications · doi:10.1038/s41467-024-51062-w · Cited by 36
Gastroenterologist perceptions of faecal microbiota transplantation
Paramsothy, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i38.10907 · Cited by 35
Clostridium difficile outbreak caused by NAP1/BI/027 strain and non-027 strains in a Mexican hospital
Morfín‐Otero, R., Garza‐González, E., Aguirre-Díaz, S. A., Escobedo-Sánchez, R., Esparza-Ahumada, S., Pérez-Gómez, H. R., Petersen-Morfín, S., González-Díaz, E., Martínez-Meléndez, A., & Rodríguez-Noriega, E. (2015) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2015.09.008 · Cited by 35
Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production
Chilton, C. H., Crowther, G. S., Ashwin, H. M., Longshaw, C. M., & Wilcox, M. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161200 · Cited by 35
Characterization of the Clostridium difficile volatile metabolome using comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry
Rees, C. A., Shen, A., & Hill, J. E. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.11.009 · Cited by 35

Authors: Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., Wilson, L. E., Winston, L. G., Cohen, J. A., Limbago, B. M., Fridkin, S. K., Gerding, D. N., & McDonald, L. C.
Affiliations: National Center for Emerging and Zoonotic Infectious Diseases (US)
Colorado Department of Public Health and Environment (US)
Oregon Health Authority (US)
University of Rochester Medicine (US)
Tennessee Department of Health (US)
Emory University (US)
Office of Readiness and Response (US)
Yale University (US)
University of New Mexico (US)
Maryland Department of Health (US)
University of California, San Francisco (US)
Loyola University Chicago (US)
ORCID: Lessa, Fernanda C.
Mu, Yi
Bamberg, Wendy M.
Dumyati, Ghinwa K.
Dunn, John R.
Farley, Monica M.
Holzbauer, Stacy M.
Meek, James I.
Phipps, Erin C.
Wilson, Lucy E.
Fridkin, Scott K.
Gerding, Dale N.
McDonald, L. Clifford
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-26
Volume: 372
Issue: 9
Pages: 825-834
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1408913
PMC: PMC10966662
OpenAlex: W2071054182
Cited by: 2,641
References: 44
Citations by year: 2026: 94 · 2025: 111 · 2024: 120 · 2023: 150 · 2022: 176 · 2021: 225 · 2020: 328 · 2019: 382 · 2018: 356 · 2017: 323 · 2016: 262 · 2015: 108
FWCI: 270.42
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion, public-domain)
eScholarship (California Digital Library) (submittedVersion)
Digital Repository at the University of Maryland (University of Maryland College Park) (public-domain)
Funders: National Institutes of Health (CC999999)
Centers for Disease Control and Prevention
Topics: Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
Keywords: Clostridium difficile infection, incidence, nosocomial infections, community-associated infections, recurrence, mortality, NAP1 strain, molecular typing, pulsed-field gel electrophoresis
MeSH terms: Adolescent, Adult, Aged, Child, Child, Preschool, Clostridium Infections, Cross Infection, Female, Humans, Infant, Male, Middle Aged, Population Surveillance, Recurrence, United States, Bacterial Typing Techniques, Incidence, Clostridioides difficile, Electrophoresis, Gel, Pulsed-Field, Age Distribution, Sex Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Burden of Clostridium difficile Infection in the United States

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks